Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen kANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — U.S. product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, FY2023
109
Period ended Dec 31, 2023
Change on a year earlier
-57.6%
257 in FY2022
History
5 years
Since FY2019
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — U.S. product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 109 | -57.6% | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 257 | -46.3% | Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 479 | +0.8% | Form 10-K (amgn-20211231.htm, filed 2022-02-16) ↗ |
| FY2020 | Dec 31, 2020 | 475 | +302.5% | Form 10-K (amgn-20201231.htm, filed 2021-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 118 | – | Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗ |
Cite this data
StockData. (2026). Amgen KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — U.S. product sales ($M) ($M), annual FY2019–FY2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_kanjinti_us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.